Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696332 · ClinicalTrials.gov registry record · Phase 2
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of ALS, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 559
- Enrollment target
- 20
- Study locations
NCT00696332: Completed Phase 2 study of ALS, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00696332 is a Phase 2 study of ALS that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 559 participants, below the 1,007-participant average among 19 other ALS trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696332, a Phase 2 study of ALS, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 559 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Talampanel
Study Locations (20)
Other
- Academic Hospital University of Leuven - ALS dept - Leuven
- C.H.U. La Timone - Service de Neurologie - Marseille
- C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques - Montpellier
- Hopital La Pitie Salpetriere - Federation de Neurologie - Paris
- Universitaetsklinik Berlin-Charite, Campus Virchow Klinikum, Neurologische Klinik - Berlin
- Berufsgenossenschaftliche Klinik Bergmannsheil, Neurologische Klinik - Bochum
- Universitaet Ulm - Ulm
- Semmelweis University, Department of Neurology - Budapest
- Sourasky MC -EMG Unit - Tel Aviv
- Fondazione "S.Maugeri" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone - Lissone (MI)
New York
- Columbia University - Neurology Institute - New York
- SUNY Upstate Medical University - Syracuse
California
- CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center - San Francisco
Kansas
- University of Kansas Medical Center - Dept of Neurology - Kansas City
Maryland
- Johns Hopkins OPC - Meyer Bldg - Baltimore
Massachusetts
- Massachusetts General Hospital-Neurology Clinical Trials Unit - Charlestown
Minnesota
- Mayo Clinic - Rochester
British Columbia
- ALS Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00696332 record still lists
NCT00696332 is an interventional study that assigns participants to a tested intervention. The registered 559 participants enrollment target is mid-sized for trials with a published cap, below the 1,007-participant average among 19 other ALS trials with a reported enrollment target (44% lower).
The record links to 1 condition, with ALS appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00696332 names 20 study sites across 10 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT00696332 about?
NCT00696332 is a clinical study titled "Talampanel for Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
What is the current status of trial NCT00696332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 559 participants. The study started on 2008-09. Estimated completion is 2010-05.
What conditions does trial NCT00696332 study?
This clinical trial studies the following conditions: ALS.
What interventions are being tested in trial NCT00696332?
The interventions under investigation include: placebo (OTHER), Talampanel (DRUG).
Who is sponsoring clinical trial NCT00696332?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00696332 being conducted?
This trial has 20 study locations across California, Kansas, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ALS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00696332's enrollment target sits among peer trials
559 5th of 19 higher than 15 of 19 other ALS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ALS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Open Label Extension Study of AMX0035 in Patients With ALS
COMPLETED · Phase 2
-
ALS/MND Natural History Study Data Repository
RECRUITING
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Amyotrophic Lateral Sclerosis (ALS) Families Project
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia